Stockreport

Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity [Yahoo! Finance]

Tango Therapeutics, Inc.  (TNGX) 
PDF “Patient safety is always our first priority and based on emerging data from the TNG348 dose escalation study, we have made the decision to discontinue further developm [Read more]